As the world waits in hope that a COVID-19 vaccine will gain approval before the end of 2020, with data readouts expected as early as October or November, data from numerous candidates for another potential line of defense against the pandemic – monoclonal antibodies (mAbs) – are also set to report in the coming months.
That is significant because even if those vaccine frontrunners can live up to expectations, they will not be a silver...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
